Taken together, these results demonstrate that inhibition of MAP3K19 significantly attenuated the development of pulmonary fibrosis in a murine bleomycin model, and these effects may be attributable, at least in part, to inhibition of the TGF-β pathway. The gene discussed is TGFB1; the disease is pulmonary fibrosis.